Skip to main content

Table 3 Drug-resistant profiles of all enrolled patients stratified by age groups

From: Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study

 15–34
(n = 734)
35–59
(n = 1593)
≥60
(n = 2090)
Total
(n = 4417)
p-value
Any drug resistance118 (16.1%)258 (16.2%)308 (14.7%)684 (15.5%)0.426
Resistant to
 INH82 (11.2%)195 (12.2%)218 (10.4%)495 (11.2%)0.226
 RIF63 (8.6%)101 (6.3%)68 (3.3%)232 (5.3%)0.000
 Rfb41 (5.6%)64 (4.0%)41 (2.0%)146 (3.3%)0.000
 EMB22 (3.0%)65 (4.1%)44 (2.1%)131 (3.0%)0.002
 PZA16 (2.2%)43 (2.7%)30 (1.4%)89 (2.0%)0.024
 Km4 (0.5%)14 (0.9%)13 (0.6%)31 (0.7%)0.558
 Am4 (0.5%)11 (0.7%)12 (0.6%)27 (0.6%)0.876
 Cm5 (0.7%)12 (0.8%)17 (0.8%)34 (0.8%)0.936
 Sm31 (4.2%)61 (3.8%)76 (3.6%)168 (3.8%)0.773
 Lfx15 (2.0%)28 (1.8%)30 (1.4%)73 (1.7%)0.495
 Mfx14 (1.9%)22 (1.4%)28 (1.3%)64 (1.4%)0.520
 Ofx15 (2.0%)27 (1.7%)29 (1.4%)71 (1.6%)0.450
 Pto8 (1.1%)14 (0.9%)23 (1.1%)45 (1.0%)0.785
 Cs1 (0.1%)3 (0.2%)2 (0.1%)6 (0.1%)0.751
 PAS5 (0.7%)24 (1.5%)29 (1.4%)58 (1.3%)0.245
INH-monoresistance40 (5.4%)114 (7.2%)162 (7.8%)316 (7.2%)0.115
RIF-monoresistance21 (2.9%)20 (1.3%)12 (0.6%)53 (1.2%)0.000
Multidrug resistance42 (5.7%)81 (5.1%)56 (2.7%)179 (4.1%)0.000
Resistance to any FQsa16 (2.2%)29 (1.8%)30 (1.4%)75 (1.7%)0.363
Resistance to any SLIDsb7 (1.0%)16 (1.0%)19 (0.9%)42 (1.0%)0.957
  1. Abbreviations: INH isoniazid, RIF rifampicin, Rfb rifabutin, EMB ethambutol, PZA pyrazinamide, Km kanamycin, Am amikacin, Cm capreomycin, Sm streptomycin, Lfx levofloxacin, Mfx moxifloxacin, Ofx ofloxacin, Pto prothionamide, Cs cycloserine, PAS para-aminosalicylic acid, FQs fluoroquinolones, SLIDs second-line injectable drugs
  2. aAny fluoroquinolones refer to levofloxacin, moxifloxacin, or ofloxacin
  3. bAny second-line injectable drugs refer to kanamycin, amikacin, or capreomycin